News | News By Subject | News by Disease News By Date | Search News

Hepatitis-B News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
3 Biotechs Leading the Pack in The Hepatitis B Space     4/17/2017
Intellia’s CEO Has Cambridge-Based Company Moving Forward on Positive in vivo Data     3/22/2017
Reeling From GlobeImmune (GBIM) Hepatitis B Termination, Gilead (GILD) Faces Merck & Co. (MRK), GlaxoSmithKline (GSK) Competition     11/22/2016
Bay Area's Dynavax (DVAX) Plunges After the FDA Spurns HEPLISAV-B Again     11/14/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Bay Area's Dynavax (DVAX) Plummeted After the FDA Cancels Advisory Meeting     9/6/2016
Roche (RHHBY) Terminates Deal with Inovio Pharma (INO), Inovio to Develop Hep B Immunotherapy Solo     8/3/2016
Dynavax (DVAX)'s Possible Hep B Win Could Prove a Threat to GlaxoSmithKline (GSK)     5/3/2016
FDA Pushes Back PDUFA Date for Dynavax (DVAX)'s Hep B Vaccine HEPLISAV-B     4/27/2016
Gilead (GILD)'s Hep B Candidate Delivers in Two Late-Stage Studies     4/15/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry     4/4/2016
ContraVir's CMX157 Bests Gilead (GILD)'s Tenofovir AF (TAF) Against Hep B Virus in Head-to-Head In-Vitro Study     3/29/2016
Benitec (BLT.AX)'s Hepatitis B Therapy Reduces HBV DNA By 98.5% in Early Study     3/8/2016
Dynavax (DVAX) Surges as Hep B Vaccine Meets Goals in Phase III Study     1/7/2016
Tekmira (TKMR) Changes Name to Arbutus Biopharma, Kills Ebola Program and Focuses on Hepatitis B     7/22/2015

News from Around the Web
Some Vaccines Tied to Lower Kids' Leukemia Risk, Baylor College of Medicine Study     2/3/2011
Focusing HIV Treatment Helps Control Concurrent Hepatitis B Infection, Wake Forest University School of Medicine Study     7/15/2009
Experts Identify Mutant Genes Linked To Hepatitis B, University of Tokyo Study     4/7/2009
Hepatitis B Vaccine Protection May Wane In Teens, Centers for Disease Control and Prevention (CDC) Study     10/24/2008
Hepatitis B Vaccine Not Associated with Multiple Sclerosis, University of Paris Study     9/30/2008
Researchers at The Wistar Institute Invigorate 'Exhausted' Immune Cells     9/19/2008
Hepatitis B Genotypes And Mutants May Influence Liver Cancer Risk, Journal of the National Cancer Institute     8/15/2008
Structure of Hepatitis B Mapped by Spraying Virus in Utrecht University Study     7/29/2008
FDA Seeks New Hepatitis Blood Donation Rules     5/21/2008
Hepatitis B Virus Triggers Cell 'Suicide' In Patients With Chronic Infection, University College London Study     4/9/2008
New Drug Found Better at Suppressing Hep B Virus     1/3/2008
Stanford University School of Medicine Researchers Find Way to Fight Treacherous Hepatitis B     10/2/2007
Korean Mummies May Provide Clues to Combat Hepatitis B, Hebrew University of Jerusalem Study     7/25/2007
Hepatitis B Drug Can Compromise HIV Treatment     6/21/2007
Sweat May Pass on Hepatitis B in Contact Sports     3/1/2007

Press Releases
Spring Bank Pharmaceuticals, Inc. Announces Collaboration With Gilead (GILD) For Hepatitis B (HBV) Phase II Study Exploring Combination Treatment Of SB 9200 And Vemlidy     7/10/2017
VBI Vaccines Reports Positive Outcome From Phase III Pre-IND Discussions With The FDA For Hepatitis B Vaccine, Sci-B-Vac     6/19/2017
Spring Bank Pharmaceuticals, Inc. Announces Top-Line Results From The Initial Cohort Of The Phase IIa Segment Of The ACHIEVE Trial, A Global Phase 2 Clinical Trial For Chronic Hepatitis B Virus (HBV)     5/24/2017
Spring Bank Pharmaceuticals, Inc. Announces The Data Safety Monitoring Board Approves Dose Escalation Of SB 9200 For The Second Cohort Of The Phase IIa Segment Of The ACHIEVE Trial, A Global Phase II Clinical Trial For Chronic Hepatitis B Virus (HBV)     5/15/2017
ContraVir To Advance Second-Generation Formulation Of Tenofovir Exalidex (TXL) For Treatment Of Hepatitis B Virus (HBV)     5/4/2017
Data Enhances Understanding Of ContraVir’s Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) And CRV431     4/24/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread     4/21/2017
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread     4/20/2017
Arrowhead Pharma (ARWR) Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress     4/20/2017
Oral Presentation At EASL Highlights ContraVir’s Tenofovir Exalidex (TXL) Antiviral Activity In Hepatitis B (HBV) Patients     4/20/2017
ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)     4/4/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders     3/14/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders     3/8/2017
Assembly Biosciences (ASMB) Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations     2/16/2017
Quest Diagnostics (DGX) Release: Company Launches Nation's First Hepatitis B Virus Quantitative Test To Help Assess Response To Antiviral Therapy     1/18/2017

//-->